Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 01, 2023 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023

PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at...
April 26, 2023 13:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease

European Commission Approval of Opfolda and Commercial Launch of Pombiliti® + Opfolda® Anticipated in 3Q 2023 Upon Approval, Pombiliti + Opfolda will be the First Two-Component Therapy in the...
March 27, 2023 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer Component...
March 01, 2023 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates

2022 Revenue Growth of 16% at CER to $329M Projecting Galafold Revenue Growth in 2023 of 12-17% at CER U.S. FDA Pre-approval Inspection for AT-GAA Now Scheduled; Approval expected in 3Q 2023 EU and...
February 27, 2023 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference...
February 22, 2023 17:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023

Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk, Forced Vital Capacity for ERT-Naïve and ERT-Experienced Participants Out to Two Years Consistent Reduction in Biomarkers Continue...
February 14, 2023 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023

PHILADELPHIA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at...
February 13, 2023 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023

PHILADELPHIA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 11 posters across its development programs will be included at the...
February 08, 2023 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference

PHILADELPHIA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma...
January 09, 2023 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook

Significant Growth in Demand with More Than 2,000 People Living with Fabry Disease on Galafold by End of 2022 2022 Full Year Revenue of ~$329M, Representing 16% YoY Growth at CER Continued...